Beta-2-microglobulin (β2M)
Category | Biochemistry >> Proteins | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Test background |
β2M is a component of the MHC class I molecule that is responsible for mediating antigen presentation to cytotoxic T cells and is ubiquitous to all cell types (with the exception of erythrocytes). Up-regulation of β2M is observed in haematological malignancy (principally MM) and may facilitate prognostic information as a function of deterioration in glomerular function. |
||||||||||||
Clinical Indications |
Monitoring of established haematological malignancy. Serum β2-microglobulin can be elevated in patients with lymphoproliferative, inflammatory and renal pathology. Its primary use in multiple myeloma is to stage tumour burden/load. |
||||||||||||
Reference range | 1.2-2.4 mg/L. The International Staging System (ISS) for multiple myeloma is described in the BCSH/UKMF guidelines and a copy for reference is provided below:
|
||||||||||||
Sample & container required | SST (gold top) | ||||||||||||
Sample volume | 0.5 mL | ||||||||||||
Transport storage | Stable at 2-8°C for 72 hours. Please freeze pending dispatch for analysis. Sample can be sent by first class post. | ||||||||||||
Turnaround time | 1 - 2 weeks | ||||||||||||
Notes | Heavily blood stained samples, old samples not stored at 4’C or -20’C, or very viscous samples may be inappropriate for analysis and/or produce equioval results. Samples must be sent fresh to the laboratory urgently. Grossly haemolysed samples are unsuitable for this assay. |